全生物监测研究参与者的血液中都检测到全氟辛酸（PFOA）。评估与血液中PFOA水平相关的健康风险具有挑战性，因为暴露指导值（EGVs）通常是以外部剂量表示的。与EGVs一致的生物监测等值（BEs）可以促进基于健康的解释。为了i）为美国环境保护署（U.S. EPA）、毒物与疾病登记局（ATSDR）和加拿大卫生部的非癌症EGVs推导出与血清/血浆PFOA相对应的BEs，并ii）与全国生物监测调查中的PFOA浓度进行比较。从EGV的起点出发，我们使用药代动力学数据/模型和不确定性因素。以妊娠啮齿动物为起点（美国环境保护署2016年，ATSDR），我们使用动物妊娠/哺乳药代动力学模型将其转化为胎儿和仔鼠的血清浓度，并使用人体妊娠/哺乳模型将等效的人类胎儿和儿童浓度转化为母体血清中的BE。成年啮齿动物的起点（加拿大卫生部）通过实验数据转化为BE。对于基于流行病学的EGVs（美国环境保护署2023年草案），BE直接基于流行病学数据或使用人体妊娠/哺乳药代动力学模型推导而来。BE与加拿大/美国的生物监测数据进行了比较。非癌症BEs（ng/mL）为684（加拿大卫生部，2018年），或在15至29（美国环境保护署2016年），6-10（ATSDR 2021）和0.2-0.8（美国环境保护署2023年草案）之间变动。加拿大健康措施调查（CHMS）2018-2019年的血清水平的95分位数略低于ATSDR的BE，而几何平均值超过了美国环境保护署（2023年草案）的非癌症BE。非癌症BE涵盖了三个数量级。加拿大/美国国家调查中的浓度高于或接近最近的非癌症EGVs的BE。版权所有 © 2023作者。由爱思唯尔有限公司出版。保留所有权利。

Perfluorooctanoic acid (PFOA) is detected in the blood of virtually all biomonitoring study participants. Assessing health risks associated with blood PFOA levels is challenging because exposure guidance values (EGVs) are typically expressed in terms of external dose. Biomonitoring equivalents (BEs) consistent with EGVs could facilitate health-based interpretations.To i) derive BEs for serum/plasma PFOA corresponding to non-cancer EGVs of the U.S. Environmental Protection Agency (U.S. EPA), the Agency for Toxic Substances and Disease Registry (ATSDR) and Health Canada, and ii) compare with PFOA concentrations from national biomonitoring surveys.Starting from EGV points of departure, we employed pharmacokinetic data/models and uncertainty factors. Points of departure in pregnant rodents (U.S. EPA 2016, ATSDR) were converted into fetus and pup serum concentrations using an animal gestation/lactation pharmacokinetic model, and equivalent human fetus and child concentrations were converted into BEs in maternal serum using a human gestation/lactation model. The point of departure in adult rodents (Health Canada) was converted into a BE using experimental data. For epidemiology-based EGVs (U.S. EPA 2023, draft), BEs were directly based on epidemiological data or derived using a human gestation/lactation pharmacokinetic model. BEs were compared with Canadian/U.S. biomonitoring data.Non-cancer BEs (ng/mL) were 684 (Health Canada, 2018) or ranged from 15 to 29 (U.S. EPA, 2016), 6-10 (ATSDR, 2021) and 0.2-0.8 (U.S. EPA, 2023, draft). Ninety-fifth percentiles of serum levels from the 2018-2019 Canadian Health Measures Survey (CHMS) and the 2017-2018 National Health and Nutrition Examination Survey (NHANES) were slightly below the BE for ATSDR, and geometric means were above the non-cancer BEs for the U.S. EPA (2023, draft).Non-cancer BEs spanned three orders of magnitude. The lowest BEs were for EGVs based on developmental endpoints in epidemiological studies. Concentrations in Canadian/U.S. national surveys were higher than or close to BEs for the most recent non-cancer EGVs.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.